Cartesian Therapeutics (RNAC) Faces Nasdaq Delisting for Low Bid Price

TL;DR

**RNAC got a delisting notice from Nasdaq for low stock price, big trouble if they can't fix it.**

AI Summary

Cartesian Therapeutics, Inc. (RNAC) announced on January 17, 2024, that it received a delisting notice from The Nasdaq Stock Market LLC because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company plans to appeal this decision, but if unsuccessful, its stock will be delisted, making it harder for investors to trade shares and potentially reducing the stock's value.

Why It Matters

This matters because delisting from Nasdaq can severely impact a stock's liquidity and investor confidence, potentially leading to a significant drop in share price and making it difficult for shareholders to sell their stock.

Risk Assessment

Risk Level: high — The risk is high because delisting from a major exchange like Nasdaq can drastically reduce a stock's liquidity and market visibility, making it a much riskier investment.

Analyst Insight

A smart investor would carefully evaluate the company's plan to regain compliance and the likelihood of a successful appeal. Given the high risk of delisting, it would be prudent to consider reducing exposure or avoiding new positions until the listing status is resolved.

Key Numbers

• $1.00 — Minimum Bid Price (The threshold Cartesian Therapeutics failed to maintain for 30 consecutive business days.)
• 30 — Consecutive Business Days (The period over which the minimum bid price was not met, triggering the delisting notice.)

Key Players & Entities

• Cartesian Therapeutics, Inc. (company) — the registrant facing delisting
• The Nasdaq Stock Market LLC (company) — the exchange issuing the delisting notice
• $1.00 (dollar_amount) — the minimum bid price requirement
• January 17, 2024 (date) — date of the earliest event reported

Forward-Looking Statements

• Cartesian Therapeutics will appeal the Nasdaq delisting decision. (Cartesian Therapeutics, Inc.) — high confidence, target: Q1 2024
• The stock price of RNAC will remain volatile as the delisting process unfolds. (RNAC) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
• $1.00 — (the "Common Stock"), has fallen below $1.00 per share for 30 consecutive business d

Filing Documents

• rnac-20240117.htm (8-K) — 29KB
• 0001453687-24-000030.txt ( ) — 152KB
• rnac-20240117.xsd (EX-101.SCH) — 2KB
• rnac-20240117_lab.xml (EX-101.LAB) — 24KB
• rnac-20240117_pre.xml (EX-101.PRE) — 12KB
• rnac-20240117_htm.xml (XML) — 3KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 17, 2024, Cartesian Therapeutics, Inc. (the "Company") received a notice from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, because the closing bid price for the Company's common stock, par value $0.0001 per share (the "Common Stock"), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1). The notification from Nasdaq has no immediate effect on the listing of the Company's Common Stock. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a grace period of 180 calendar days, or until July 15, 2024, to regain compliance with the minimum closing bid price requirement for continued listing. To regain compliance, the closing bid price of the Company's Common Stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180-day grace period. If the Company does not regain compliance with Rule 5450(a)(1) by July 15, 2024, the Company may be eligible for an additional 180-calendar day compliance period. To qualify for the additional 180-calendar day compliance period, the Company would be required to transfer the listing of the Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market and meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement, and provide written notice to Nasdaq of its intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: January 19, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR